BrainStorm Can't Shed Investors' ALS Treatment Trial Claims

By Emilie Ruscoe · September 16, 2025, 7:07 PM EDT

Biopharmaceutical company BrainStorm Cell Therapeutics Inc. must face a proposed investor class alleging it misrepresented feedback from the U.S. Food and Drug Administration regarding clinical trials for an ALS product candidate...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login